Matthew R Hight
Overview
Explore the profile of Matthew R Hight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen A, Li J, Hight M, McKinley E, Fu A, Payne A, et al.
Clin Cancer Res
. 2020 Sep;
26(22):5914-5925.
PMID: 32933996
Purpose: Pancreatic cancer is among the most aggressive malignancies and is rarely discovered early. However, pancreatic "incidentalomas," particularly cysts, are frequently identified in asymptomatic patients through anatomic imaging for unrelated...
2.
Buck J, Saleh S, Claus T, Lovly C, Hight M, Nickels M, et al.
Bioorg Med Chem Lett
. 2020 Jul;
30(16):127257.
PMID: 32631505
N-[F]fluoroacetylcrizotinib, a fluorine-18 labeled derivative of the first FDA approved tyrosine kinase inhibitor (TKI) for the treatment of Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), crizotinib, was successfully...
3.
Zhang Q, Jeppesen D, Higginbotham J, Demory Beckler M, Poulin E, Walsh A, et al.
Cell Mol Gastroenterol Hepatol
. 2018 Jun;
5(4):627-629.e6.
PMID: 29930982
No abstract available.
4.
Schulte M, Hight M, Ayers G, Liu Q, Shyr Y, Washington M, et al.
Mol Imaging Biol
. 2016 Oct;
19(3):421-428.
PMID: 27770401
Purpose: This study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake...
5.
Hassanein M, Hight M, Buck J, Tantawy M, Nickels M, Hoeksema M, et al.
Mol Imaging Biol
. 2015 May;
18(1):18-23.
PMID: 25971659
Purpose: Alanine-serine-cysteine transporter 2 (ASCT2) expression has been demonstrated as a promising lung cancer biomarker. (2S,4R)-4-[(18)F]Fluoroglutamine (4-[(18)F]fluoro-Gln) positron emission tomography (PET) was evaluated in preclinical models of non-small cell lung...
6.
Hight M, Cheung Y, Nickels M, Dawson E, Zhao P, Saleh S, et al.
Clin Cancer Res
. 2014 Feb;
20(8):2126-35.
PMID: 24573549
Purpose: Apoptosis, or programmed cell death, can be leveraged as a surrogate measure of response to therapeutic interventions in medicine. Cysteine aspartic acid-specific proteases, or caspases, are essential determinants of...
7.
Tang D, McKinley E, Hight M, Uddin M, Harp J, Fu A, et al.
J Med Chem
. 2013 Mar;
56(8):3429-33.
PMID: 23521048
Focused library synthesis and structure-activity relationship development of 5,6,7-substituted pyrazolopyrimidines led to the discovery of 2-(5,7-diethyl-2-(4-(2-fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide (6b), a novel translocator protein (TSPO) ligand exhibiting a 36-fold enhancement in affinity compared...
8.
Eubank J, Nouar F, Luebke R, Cairns A, Wojtas L, Alkordi M, et al.
Angew Chem Int Ed Engl
. 2012 Sep;
51(40):10099-103.
PMID: 22961923
No abstract available.
9.
Tang D, Hight M, McKinley E, Fu A, Buck J, Smith R, et al.
J Nucl Med
. 2012 Jan;
53(2):287-94.
PMID: 22251555
Unlabelled: There is a critical need to develop and rigorously validate molecular imaging biomarkers to aid diagnosis and characterization of primary brain tumors. Elevated expression of translocator protein (TSPO) has...
10.
Eubank J, Wojtas L, Hight M, Bousquet T, Kravtsov V, Eddaoudi M
J Am Chem Soc
. 2011 Jun;
133(44):17532-5.
PMID: 21675767
A new pillaring strategy, based on a ligand-to-axial approach that combines the two previous common techniques, axial-to-axial and ligand-to-ligand, and permits design, access, and construction of higher dimensional MOFs, is...